Related Experiment Video
Updated: Apr 7, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
14.0K
[Vonoprazan: a novel potassium-competitive acid blocker]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 14, 2015
Summary
Vonoprazan, a new potassium-competitive acid blocker, demonstrates superior efficacy compared to lansoprazole for acid-related diseases. Long-term safety requires further investigation due to elevated gastrin levels.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Acid-related diseases pose significant health challenges.
- Potassium-competitive acid blockers (P-CABs) represent a novel therapeutic class.
Purpose of the Study:
- To evaluate the efficacy and safety of vonoprazan in treating acid-related disorders.
- To compare vonoprazan with lansoprazole in phase III clinical trials.
Main Methods:
- Phase III clinical trials comparing vonoprazan and lansoprazole.
- Assessment of healing rates in gastroesophageal reflux disease (GERD).
- Evaluation of Helicobacter pylori eradication rates with triple therapy.
Main Results:
- Vonoprazan showed non-inferior or superior efficacy to lansoprazole across various acid-related diseases.
- Vonoprazan was superior in healing severe GERD (Los Angeles grade C and D).
- Triple therapy with vonoprazan achieved >90% H. pylori eradication; adverse events were comparable to lansoprazole.
Conclusions:
- Vonoprazan is a potent and effective treatment for acid-related diseases.
- The profound acid suppression by vonoprazan leads to increased serum gastrin levels, necessitating long-term safety monitoring.
More Related Videos
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
01:20Antiepileptic Drugs: Potassium Channel Activators
973
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
973
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
3.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:19Depolarizing Blockers: Pharmocokinetics
724
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
724
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
1.3K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.3K